文献速递认知障碍与痴呆

按APOE基因型分层分析阿尔茨海默病全外显子组测序数据

Analysis of Whole-Exome Sequencing Data for Alzheimer Disease Stratified by APOE Genotype.
PubMed 文献 · JAMA Neurol · 2019-01-01

该研究基于阿尔茨海默病测序项目10 441名非西班牙裔白人参与者,按APOE ε4携带状态分层,用全外显子组测序寻找与AD相关的低频和罕见变异。在ε4非携带者中发现AC099552的rs536940594和GPAA1的rs138412600与AD全基因组显著关联,在ε4携带者中发现OR8G5、IGHV3-7和SLC24A3基因水平显著关联。

要点

  • ε4非携带者中GPAA1的rs138412600与AD风险相关(OR 1.78,meta-P 7.81×10-8)
  • ε4携带者中IGHV3-7、SLC24A3和OR8G5显示基因水平显著关联
  • GPAA1还影响脑内GPAA1和FOXG1表达及整体认知功能

核心结论

  • 在APOE ε4携带与非携带亚组中均发现多个可能的AD新关联,涉及单个及聚合罕见变异,强化已知通路并提示额外通路。

研究设计与样本

  • 发现阶段纳入阿尔茨海默病测序项目中10 441名非西班牙裔白人参与者。
  • 在2个独立全外显子组测序数据集(1766例AD,2906例对照)和1个芯片基因型插补数据集(8728例AD,9808例对照)中寻求重复。
  • 生物信息与功能分析使用纵向队列样本(402例AD,647例对照)的临床、认知、神经病理、全外显子组测序和基因表达数据。
  • 数据分析时间为2017年3月至2018年9月。

主要发现

  • 在3145例AD和4213例无ε4对照(平均[SD]年龄83.4[7.6]岁;4363[59.3%]女性)中,发现AC099552的rs536940594(OR 88.0;95%CI 9.08-852.0;P=2.22×10-7)和GPAA1的rs138412600(OR 1.78;95%CI 1.44-2.2;meta-P=7.81×10-8)达全基因组显著。
  • GPAA1与脑内GPAA1表达(β=-0.08;P=.03)、其抑制性转录因子FOXG1(β=0.13;P=.003)及整体认知功能(β=-0.53;P=.009)相关。
  • 在2377例AD和706例ε4携带对照(平均[SD]年龄75.2[9.6]岁;1668[54.1%]女性)中,OR8G5(P=4.67×10-7)、IGHV3-7(P=9.75×10-16)和SLC24A3(P=2.67×10-12)达基因水平显著关联(阈值P≤6.35×10-7)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Previous genome-wide association studies of common variants identified associations for Alzheimer disease (AD) loci evident only among individuals with particular APOE alleles. OBJECTIVE: To identify APOE genotype-dependent associations with infrequent and rare variants using whole-exome sequencing. DESIGN, SETTING, AND PARTICIPANTS: The discovery stage included 10 441 non-Hispanic white participants in the Alzheimer Disease Sequencing Project. Replication was sought in 2 independent, whole-exome sequencing data sets (1766 patients with AD, 2906 without AD [controls]) and a chip-based genotype imputation data set (8728 patients with AD, 9808 controls). Bioinformatics and functional analyses were conducted using clinical, cognitive, neuropathologic, whole-exome sequencing, and gene expression data obtained from a longitudinal cohort sample including 402 patients with AD and 647 controls. Data were analyzed between March 2017 and September 2018. MAIN OUTCOMES AND MEASURES: Score, Firth, and sequence kernel association tests were used to test the association of AD risk with individual variants and genes in subgroups of APOE ε4 carriers and noncarriers. Results with P ≤ 1 × 10-5 were further evaluated in the replication data sets and combined by meta-analysis. RESULTS: Among 3145 patients with AD and 4213 controls lacking ε4 (mean [SD] age, 83.4 [7.6] years; 4363 [59.3.%] women), novel genome-wide significant associations were obtained in the discovery sample with rs536940594 in AC099552 (odds ratio [OR], 88.0; 95% CI, 9.08-852.0; P = 2.22 × 10-7) and rs138412600 in GPAA1 (OR, 1.78; 95% CI, 1.44-2.2; meta-P = 7.81 × 10-8). GPAA1 was also associated with expression in the brain of GPAA1 (β = -0.08; P = .03) and its repressive transcription factor, FOXG1 (β = 0.13; P = .003), and global cognition function (β = -0.53; P = .009). Significant gene-wide associations (threshold P ≤ 6.35 × 10-7) were observed for OR8G5 (P = 4.67 × 10-7), IGHV3-7 (P = 9.75 × 10-16), and SLC24A3 (P = 2.67 × 10-12) in 2377 patients with AD and 706 controls with ε4 (mean [SD] age, 75.2 [9.6] years; 1668 [54.1%] women). CONCLUSIONS AND RELEVANCE: The study identified multiple possible novel associations for AD with individual and aggregated rare variants in groups of individuals with and without APOE ε4 alleles that reinforce known and suggest additional pathways leading to AD.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Ma Y, Jun GR, Zhang X, et al. Analysis of Whole-Exome Sequencing Data for Alzheimer Disease Stratified by APOE Genotype. JAMA Neurol. 2019. PMID: 31180460. doi:10.1001/jamaneurol.2019.1456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。